Answers are grounded in this paper and cite their sources.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects shared pathophysiology across metabolic, renal and cardiovascular systems, yet circulating proteins with causal effects spanning multiple CKM domains remain unclear. We aimed to identify and prioritize cross-domain candidate proteins using an integrative, dual-platform plasma proteogenomic framework. Methods: We combined genetic causal inference, statistical colocalization, single-cell expression mapping, and structure-based druggability assessment. Cis-protein quantitative trait loci (cis-pQTL) instruments were derived from two independent plasma proteomic platforms, UKB-PPP (2,030 proteins with valid cis instruments) and deCODE (1,640 proteins). Genetic causal inference (two-sample Mendelian randomization) was performed against seven CKM-related outcomes across the metabolic (type 2 diabetes [T2D], body mass index [BMI]), renal (estimated glomerular filtration rate [eGFR], chronic kidney disease) and cardiovascular (coronary artery disease, heart failure, stroke) domains. Proteins showing false discovery rate (FDR)-significant associations in at least two CKM domains independently on both platforms were prioritized, and cross-platform directional concordance was evaluated as a robustness measure. Prioritized proteins were followed by colocalization, and characterization using single-cell expression, disease-association and druggability resources. Structural and ligand-efficiency analyses were performed for the leading candidate using its co-crystallized inhibitor complex. Results: Proteome-wide analysis yielded 9,734 (UKB-PPP) and 8,837 (deCODE) protein-outcome estimates, with 77.9% two-platform directional concordance. Cross-domain prioritization identified six proteins (ARG1, GSTA1, INHBB, ITIH1, NCAN, SHBG), all acting across the metabolic-renal axis. Colocalization provided strong support for GSTA1 with eGFR (posterior probability of a shared causal variant 0.97) and ARG1 with BMI (0.93). Genetically higher GSTA1 was associated with lower eGFR and higher T2D risk, with kidney expression confined to proximal tubule cells. Genetically higher ARG1 was associated with lower BMI and lower T2D risk, consistent with hepatocyte-restricted expression. Both proteins were small-molecule tractable. For GSTA1, the inhibitor-bound structure (PDB 1GSF) showed a deep, enclosed H-site, and three chemotypes with previously reported low-micromolar potency against recombinant hGSTA1-1 (ethacrynic acid and the dietary flavonols fisetin and myricetin) all exceeded the lead-like ligand-efficiency threshold (0.30 kcal mol-1 per heavy atom). Conclusions: Using dual-platform proteogenomics, we identify genetically supported cross-metabolic-renal candidate proteins in CKM syndrome, with GSTA1 and ARG1 emerging as the most robust, pharmacologically tractable candidates. These findings nominate actionable targets and mechanistic entry points for CKM syndrome.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: